These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 12720157

  • 21. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia.
    Gertz MA, Geyer SM, Badros A, Kahl BS, Erlichman C.
    Clin Lymphoma; 2005 Mar; 5(4):282-4. PubMed ID: 15794866
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.
    Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A.
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):765-74. PubMed ID: 21521129
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
    Tolcher AW.
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
    [Abstract] [Full Text] [Related]

  • 27. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC.
    J Clin Oncol; 2005 May 20; 23(15):3404-11. PubMed ID: 15824414
    [Abstract] [Full Text] [Related]

  • 28. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U, Leech SH, Olie RA, Simões-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J, Nalin CM, Stahel RA.
    Clin Cancer Res; 2000 Jun 20; 6(6):2547-55. PubMed ID: 10873111
    [Abstract] [Full Text] [Related]

  • 29. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5048-57. PubMed ID: 15297406
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.
    Clin Cancer Res; 2006 Aug 15; 12(16):4940-8. PubMed ID: 16914583
    [Abstract] [Full Text] [Related]

  • 32. Induction of apoptosis by G3139 in melanoma cells.
    Benimetskaya L, Lai JC, Khvorova A, Wu S, Miller P, Stein CA.
    Ann N Y Acad Sci; 2005 Nov 15; 1058():235-45. PubMed ID: 16394140
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group.
    J Clin Oncol; 2006 Oct 10; 24(29):4738-45. PubMed ID: 16966688
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
    Kim R, Tanabe K, Uchida Y, Emi M, Toge T.
    Int J Mol Med; 2003 Jun 10; 11(6):799-804. PubMed ID: 12736725
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
    Kausch I, Jiang H, Thode B, Doehn C, Krüger S, Jocham D.
    Eur Urol; 2005 May 10; 47(5):703-9. PubMed ID: 15826766
    [Abstract] [Full Text] [Related]

  • 40. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R, Tanabe K, Emi M, Uchida Y, Toge T.
    Int J Oncol; 2004 Jan 10; 24(1):5-17. PubMed ID: 14654935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.